ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer - PubMed
3 hours ago
- #breast cancer
- #ctDNA
- #endocrine therapy
- Endocrine therapy (ET) resistance in ER+ advanced breast cancer is often linked to ESR1 mutations.
- Tumor ER transcriptional activity and ctDNA genomics/dynamics stratify response to ET, including giredestrant.
- ctDNA genomic landscape post-first-line therapy is diverse and influenced by CDK4/6 inhibitor exposure.
- ER activity in ESR1-mutant tumors remains comparable to early breast cancer but is reduced in non-mutant cases.
- Maintained ER activity is associated with giredestrant benefit.
- Early ctDNA clearance identifies responding patients.
- Low ER activity and high ctDNA burden predict rapid clinical progression.
- Findings support personalizing breast cancer therapies by integrating liquid biopsies with tissue-based signatures.